Stay Safe with IXCHIQ®: The First Chikungunya Vaccine in the UK

The MHRA has approved IXCHIQ®, the UK’s first vaccine for chikungunya, a mosquito-borne viral illness found in parts of Africa, Asia, the Americas, and increasingly in Europe. This vaccine is crucial for adults aged 18 to 59 who are travelling to areas with known chikungunya outbreaks.

What is Chikungunya?

Chikungunya virus spreads through mosquito bites. It causes high fever, severe joint pain, muscle aches, rash, and fatigue. Symptoms usually resolve in one to two weeks. However, joint pain can persist for months or even years, especially in older adults. Currently, there is no specific treatment available for chikungunya.

About the Vaccine (IXCHIQ®)

• Developed by Valneva

• Approved by MHRA in February 2025

• Single-dose live attenuated vaccine

• Shown to trigger protective antibodies in 99% of recipients

• Immunity lasts at least three years

  
  

This vaccine is prescription-only and is not suitable for those who are immunocompromised, pregnant, or have a history of thymus disorders.

Safety Review and Age Restrictions

In early 2025, rare but serious side effects were reported in elderly people with underlying health conditions. This led the MHRA to temporarily restrict use in those aged 60 and over. The European Medicines Agency (EMA) has since lifted its own restriction, noting that the vaccine remains effective and may benefit older people. However, the MHRA’s restriction in the UK is still in effect.

Who Should Consider the Vaccine?

According to JCVI guidance, IXCHIQ® is recommended for:

• Travellers to outbreak regions

• Long-stay or frequent travellers to endemic areas

• Laboratory workers handling the virus

  
  

Currently, it is not recommended for those aged 60 or over in the UK due to the ongoing MHRA review.

Common Side Effects

Side effects are typically mild to moderate and may include:

• Fever

• Headache

• Muscle or joint pain

• Fatigue

• Redness or swelling at the injection site

• Temporary reduction in white blood cells

  
  

Anyone experiencing side effects should report them via the MHRA Yellow Card scheme.

The Importance of Vaccination

Vaccination is a vital step in protecting yourself from chikungunya. The IXCHIQ® vaccine can help you avoid the severe symptoms associated with this virus. If you plan to travel to areas where chikungunya is prevalent, getting vaccinated is a wise choice.

Book a Consultation

At Pulteney Pharmacy, we offer travel health advice and vaccination consultations, including assessment for IXCHIQ® eligibility. If you're planning to travel to a region where chikungunya is a risk, speak to our team.

Visit us at pulteneypharmacy.com to book an appointment. We are here to ensure your health and safety while you travel.

Why Choose Pulteney Pharmacy?

Choosing Pulteney Pharmacy means you are opting for a local health hub that prioritises your well-being. Our team is dedicated to providing you with the best health advice and services. We understand the importance of accessible healthcare, and we strive to make it hassle-free for you.

Conclusion

In conclusion, the IXCHIQ® vaccine is a significant advancement in preventing chikungunya. If you are planning to travel, don’t wait. Protect yourself by booking a consultation with us today. Your health is our priority, and we are here to support you every step of the way.

Stay safe and healthy with Pulteney Pharmacy!